Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo Controlled Trial of Aldafermin (NGM282) for Treatment of Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
Conditions
Interventions
Aldafermin
Placebo
Locations
1
United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
December 1, 2021
Primary Completion Date
November 8, 2022
Completion Date
November 8, 2022
Last Updated
October 12, 2023
NCT07338565
NCT07103772
NCT06530836
NCT03898856
NCT03729271
NCT04855799
Lead Sponsor
Michael Camilleri, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions